Review: Lower IQ With Prenatal Exposure to Sodium Valproate

This article originally appeared here.
Share this content:
Review: Lower IQ With Prenatal Exposure to Sodium Valproate
Review: Lower IQ With Prenatal Exposure to Sodium Valproate

(HealthDay News) -- Prenatal exposure to sodium valproate (VPA) is associated with a reduction in offspring IQ, according to a review published online Oct. 30 in The Cochrane Library.

Rebecca Bromley, Clin.Psy.D., Ph.D., from the University of Manchester in the United Kingdom, and colleagues examined the effect of prenatal exposure to antiepileptic drugs on neurodevelopmental outcomes in offspring. A systematic review of the literature was conducted and data were included from 22 prospective cohort studies and six registry-based studies.

The researchers found that the developmental quotient (DQ) was lower in children exposed to carbamazepine versus those born to women without epilepsy and to those born to women with untreated epilepsy; further analysis indicated that these results were due to within-study variability. The DQ and IQ of children exposed to VPA were lower than that of children born to untreated women. The IQ of children exposed to VPA was lower than that of children born to women without epilepsy and that of those exposed to carbamazepine. In six studies there was a dose effect reported for VPA, with higher doses associated with poorer cognitive outcome.

"The most important finding is the reduction in IQ in the VPA exposed group, which are sufficient to affect education and occupational outcomes in later life," the authors write. "However, for some women VPA is the most effective drug at controlling seizures."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »